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Abstract
Background: B-type natriuretic peptide (BNP) is a 32 
amino acid cardiac hormone routinely measured by 
immunoassays to diagnose heart failure. While it is 
reported that immunoassay results can vary up to 45%, no 
attempt of standardization and/or harmonization through 
the development of certified reference materials (CRMs) or 
reference measurement procedures (RMPs) has yet been 
carried out.
Methods: B-type natriuretic peptide primary calibrator 
was quantified traceably to the International System of 
Units (SI) by both amino acid analysis and tryptic diges-
tion. A method for the stabilization of BNP in plasma fol-
lowed by protein precipitation, solid phase extraction 
(SPE) and liquid chromatography (LC) mass spectrometry 
(MS) was then developed and validated for the quantifica-
tion of BNP at clinically relevant concentrations (15–150 
fmol/g).
Results: The candidate reference method was applied to 
the quantification of BNP in a number of samples from 
the UK NEQAS Cardiac Markers Scheme to demonstrate its 
applicability to generate reference values and to prelimi-
nary evaluate the commutability of a potential CRM. The 
results from the reference method were consistently lower 
than the immunoassay results and discrepancy between 
the immunoassays was observed confirming previous data.
Conclusions: The application of the liquid chromatogra-
phy-mass spectrometry (LC-MS) method to the UK NEQAS 
samples and the correlation of the results with the immu-
noassay results shows the potential of the method to sup-
port external quality assessment schemes, to improve 
understanding of the bias of the assays and to establish 
RMPs for BNP measurements. Furthermore, the method 
has the potential to be multiplexed for monitoring circu-
lating truncated forms of BNP.
Keywords: 1-32 B-type natriuretic peptide (BNP) reference 
method; brain natriuretic peptides; isotope dilution mass 
spectrometry; standardization.
Introduction
B-type natriuretic peptide (BNP) and N-terminal proBNP 
(NT-proBNP) are cardiac biomarkers secreted as proBNP, 
the prohormone of BNP, by the myocytes of the left ven-
tricle in response to volume overload in an event of con-
gestive heart failure [1]. In 2012, specific age-independent 
decision cut-offs for both BNP (≤100 ng/L) and NT-proBNP 
(≤300 ng/L) were endorsed [2] and measurements of cir-
culating BNP are currently used in clinical practice for the 
diagnosis of acute and chronic heart failure, risk stratifi-
cation and monitoring response to therapy [3].
A number of immunoassays specific for BNP and NT-
proBNP analysis are commercially available and studies 
have been performed to assess their performance [4, 5]. 
The results of the CardioOrmoCheck study, for example, 
highlighted discrepancy between immunoassays specific 
for BNP and discussed the requirement for measurement 
standardization [6].
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A recognized route for standardization of clinical 
laboratory measurements is the development of ref-
erence measurement procedures including reference 
methods and certified reference materials (CRM) [7, 8]. 
In the biological area, the poor definition of the meas-
urand has been identified as the major bottleneck and 
barrier for the development of reference methods and 
commutable reference materials. Immunoassays target-
ing BNP are currently calibrated with recombinant or 
synthetic BNP and the samples distributed by most of 
the quality assurance schemes are plasma spiked with 
BNP. It is, however, now accepted that proBNP, 1-32 BNP 
and NT-proBNP are not the only forms circulating [9–11]. 
The correlation between a reference method specific for 
what believed to be the measurand and immunoassays 
becomes in this case the first mandatory step to evalu-
ate the potential of reference measurement procedures 
to improve measurement accuracy and precision in 
clinical laboratories.
Over the past decade a number of papers have been 
published on the development of methods for the quan-
tification of BNP by mass spectrometry (MS) [10, 12–16]. 
Issues including the very low concentration of BNP 
in plasma, the difficulties associated with measuring 
large intact peptides by MS and poor stability of BNP 
in plasma (half-life of 22.6  min) have however limited 
their further development for application in clinical 
laboratories.
Here we present for the first time the development 
of a reference liquid chromatography-mass spectrometry 
(LC-MS) method for quantification of BNP in plasma at 
clinically relevant concentrations. The method developed 
was applied to quantify BNP in a number of UK NEQAS 
Cardiac Markers Scheme samples and the correlation 
between the LC-MS results and immunoassay results was 
evaluated to define the utility of the method to establish 
reference measurement procedures for BNP.
Materials and methods
Materials
All materials were from Sigma-Aldrich (St. Louis, MO, USA) unless 
otherwise stated and details on the purity of the materials can 
be found in the Supplemental material file (A). Formic acid (FA) 
and Tris(2-carboxyethyl)phosphine hydrochloride (TCEP*HCl) 
were from Thermo Fisher Scientific (Loughborough, UK), HCl 
from ROMIL (Cambridge, UK). N-methyl-N-(trimethylsilyl)-trif-
luoroacetamide (MSTFA) containing 1% trimethylchlorosilane 
(TMCS) from Restek Corporation (Belleforte, PA, USA). Modified 
sequencing grade trypsin was supplied by Roche Applied Science 
(Penzberg, Germany). L-methionine was from Fluka (Buchs, Swit-
zerland). HPLC Optigrade organic solvents were from LGC (Ted-
dington, UK).
The 32 amino acid BNP was from Sigma-Aldrich and the isotopi-
cally labeled BNP (SPKMV(13C5,15N)Q-G(13C2,15N)S-G(13C2,15N)-CF-
G(13C2,15N)-RKMDR-I(13C6,15N)-SSSSGLGC-K(13C6,15N2)-VLRRH) 
from CPC Scientific (Sunnydale, CA, USA). The average molecular 
weight was 3464.1020  g/mols. The lyophilized peptides were dis-
solved in water:acetonitrile (90:10 v/v) containing 0.1% FA (v/v) and 
further dilutions were carried out in water containing 500 μg/g BSA 
and 0.5% FA (v/v). Certified amino acids from the National Metrology 
Institute of Japan (NMIJ, Tsukuba, Japan) were used for quantifica-
tion of BNP.
MVQGSGCFGR, MVQGSGC-F(13C9,15N)-GR, ISSSSG-LGCK and 
ISSSS-G(13C2,15N)-L(13C6,15N)-GCK were from AnaSpec (Fremont, 
CA, USA) and in-house quantified against the NIST amino acid CRM 
(2389a) (NIST, Gettysburg, PA, USA). Human K2 ethylenediaminetet-
raacetic acid (EDTA) mixed gender plasma was purchased from Sera 
Laboratories International (Haywards Heath, UK).
Methods
Quantification of peptides: The method developed for the SI-trace-
able quantification of BNP and BNP tryptic digest peptide standards 
by amino acid analysis was a modification of a method previously 
described [17, 18]. The samples were hydrolyzed at 190 °C for 30 min 
in an ETHOZ EZ Microwave Digestion System (Milestone, Sorisole, 
Italy) equipped with a protein hydrolysis kit containing 30  mL of 
6  M hydrochloric acid (HCl). Each hydrolysis included a reagent 
blank (solvents only), natural amino acids control, labeled amino 
acids control, a recovery vial, two calibration blends and two sam-
ple blends. The hydrolyzed samples were lyophilized, reconstituted 
in 80 μL MSTFA and analyzed by gas chromatography-mass spectro-
metry (GC-MS) [18]. Three hydrolyses containing two sample blends, 
and two calibration blends were performed. Samples were indepen-
dently prepared before each hydrolysis. The final results were the 
average from all amino acid results (n = 6).
Quantification of BNP using tryptic digestion was performed 
by isotope dilution mass spectrometry (IDMS) using isotopically 
labeled peptides as internal standards [17–19]. Tryptic digestion 
was optimized as described by Cryar et al. [18]. Ultimately 250 μL 
of sample blends and calibration blends in 500 mM TRIS buffer and 
10  mM Ca2+ (pH 8.10) were reduced and alkylated with 200  nmol 
TCEP (37 °C, 60  min) and 400  nmol: S-methyl methanethiosul-
fonate (MMTS) (in the dark, 37 °C, 30 min). The samples were tryp-
tic digested at 37 °C for 2 h with two additions of 3.5 μg of trypsin. A 
Q-TRAP 4000 (ABSciex, Framingham, MA, USA) coupled to a 1100 
HPLC (Agilent Technologies Inc, Santa Clara, CA, USA) was used. 
Separation was achieved on a XBridge BEH C18 column (3.5 μm, 
2.1 × 150 mm, pore diameter of 130 Å; Waters Corporation, Milford, 
MA, USA) at 60 °C. Flow rate was 100 μL/min, injection volume 10 
μL. Mobile phases were: (A) water 0.1% FA (v/v) and (B) acetonitrile 
0.1% FA (v/v). A linear gradient from 5 to 40% of (B) over 30 min 
was applied. Details of the MS settings are reported in the Supple-
mental material file (B). The following selective reaction monitoring 
Brought to you by | University of Reading
Authenticated
Download Date | 6/6/17 11:09 AM
Torma et al.: A reference method for the cardiac marker 1-32 B-type natriuretic peptide      3
(SRM) experiments were set up: 729.4/739.4  → 544.3/549.3 for 
MVQGSGC(Methylthio)FGR/MVQGSGC(Methylthio)-F(13C9,15N)-
GR and 784.4/793.5  → 492.8/497.3 for ISSSSGLGC(Methylthio)K/
ISSSSG(13C2,15N)-L(13C6,15N)-GC (Methylthio)K.
LC-MS/MS analysis of BNP: The BNP stock solution was analyzed 
for potential impurities on an Agilent Q-TOF 6530 equipped with a 
JetStream (AJST) electrospray ionization (ESI) source. Quantifica-
tion of BNP was performed on an Agilent 6490 Triple Quadrupole 
(QqQ) also equipped with an AJST ESI source. Both instruments 
were coupled to an Agilent 1290 UHPLC. Identical source and 
chromatographic conditions were used for the two sets of experi-
ments and details of the source conditions are reported in the Sup-
plemental material file (C). For the IDMS quantification of BNP by 
QqQ-SRM, experiments were set up by fragmenting the 6 +  charge 
state of the intact precursor ion (BNP: m/z 578.3, BNP*: m/z 583.3) 
and monitoring the 4 +  y26 product ion (BNP: m/z 699.2, BNP*: 
m/z 705.2) The dwell time was 100 ms, fragmentor voltage 380.0 
V. Collision energy (CE) and cell acceleration voltage were 18 V 
and 1 V, respectively. All data were acquired in positive ion mode. 
Chromatographic separation was performed by using a Phenom-
enex Aeris PEPTIDE XB-C18 column (2.6 μm; 2.1 × 250 mm, 90 Å) 
at 60 °C. A 20-min linear gradient from 1 to 20% (B) was applied. 
Mobile phases were: (A) water 0.5% FA (v/v) and (B) acetonitrile 
0.5% FA (v/v). The flow rate was 400 μL/min. Dimethyl-sulfoxide 
(DMSO) was post-column infused at 1 μL/min. Injection volume 
was 10 μL.
Sample clean-up: Details on sample clean up are provided in the 
Supplemental material file (D). Briefly, protein precipitation (PPT) 
was achieved by adding 1.5 mL of water:acetonitrile (20:80; v/v) con-
taining 0.5% FA to 0.5 mL of plasma samples. Solid phase extraction 
(SPE) was performed on a STRATA XL cartridge (200 mg/3 mL, 300 Å, 
100 μm; Phenomenex, Macclesfield, UK) by eluting BNP with 4 mL 
water:acetonitrile (65:35; v/v) containing 0.5% FA.
Results and discussion
Characterization and quantification of BNP 
primary calibrator
The BNP stock solution was analyzed by LC-MS using a 
Q-TOF instrument to identify peptidic impurities which 
could compromise the accuracy of the quantification 
results. The main impurities identified by accurate mass 
(≤ 4ppm) were deletion products of BNP including a 
peptide missing one serine (S) and one proline (P) residue, 
peptides missing one S residue and peptides missing 
one glycine (G) residue. Peptides corresponding to BNP 
with oxidized methionine (positions 4 and 15) were also 
detected. An approximate calculation of the relative per-
centage of impurities was performed by assuming that 
the impurities had the same ionization efficiency as the 
BNP. The impurities missing both S and P were ~1.6% of 
the major peak, missing one S were ~2.3% and one G were 
1.5%. The amount of oxidized BNP in the stock solution 
was less than 1%.
The peptidic content of the BNP stock solution was SI 
traceably quantified by amino acid analysis as described 
in the Methods section. The results obtained are shown 
in Figure 1. It can be seen that the BNP concentration 
calculated from the amino acid P was lower than the 
BNP concentrations calculated from the other amino 
acids, but within uncertainty. This could be justified by 
the presence of the impurity missing the residues S and 
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Figure 1: Results from the quantification of the BNP stock solution by amino acid analysis.
Each point represents the concentration of BNP in nmol/g [m(nmol/g)] calculated for each amino acid (G, L, V, K, I, P, R, F, x-axis) from three 
independent experiments (QUANT#1, QUANT#2 and QUANT#3). The gray line (BNP) is the concentration of BNP calculated as the average of 
the amino acid results. The two dotted lines are the expanded uncertainties (U, k = 2) of BNP concentration calculated as described in the 
Supplemental material file (E).
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P (-SP) previously identified. No significant difference 
was observed for the value obtained from the amino acid 
glycine (G). All stable amino acids were included in the 
calculation of the concentration of the BNP stock solution 
(including proline and glycine), thus including the vari-
ability associated to the presence of peptidic impurities. 
The standard and combined uncertainties were  calculated 
in accordance with the ISO Guide to the Expression of 
Uncertainty in Measurement [20] and EURACHEM guide-
lines [21]. Further purification of the BNP material, quan-
tification of the impurities by using appropriate internal 
standards and a full purity assessment of the standard will 
improve accuracy and reduce uncertainty of the measure-
ments and will have to be performed for the production 
of a CRM. The concentration of the BNP stock solution 
determined via amino acid analysis was confirmed by 
IDMS of the tryptic digested peptides using the isotopi-
cally labeled peptides as internal standards. A value of 
(111.92 ± 2.03) nmol/g was obtained by amino acid analy-
sis and a value of (100.63 ± 10.69) nmol/g was calculated 
from the tryptic digestion approach. Both uncertainties 
are combined uncertainties (95% confidence interval) and 
were calculated in accordance with the ISO Guide to the 
Expression of Uncertainty in Measurement [20] and EURA-
CHEM guidelines [21]. The concentration of BNP from the 
amino acid analysis results was used for the quantifica-
tion experiments of BNP in plasma. The overlap between 
the acid hydrolysis and tryptic digestion values confirms 
the accuracy of the amino acid analysis method here 
optimized. By combining the amino acid analysis experi-
ments and the tryptic digestion experiments, 87% of the 
BNP sequence was quantified. The agreement within the 
calculated uncertainty of the quantification results from 
the individual amino acid and the tryptic digest peptides 
suggests that further purification would mostly reduce 
measurement uncertainty. While full purity assessment 
experiments of the standard are on-going, the uncertainty 
here obtained and the material were considered fit-for-
purpose for this study.
Quantification of BNP in plasma
Analysis of large peptides/proteins by ESI MS is facilitated 
by the formation of multiply charged ions. This, however, 
renders the detection of large peptides at low concentra-
tion (e.g. pg/g and fmol/g) challenging as the ion abun-
dance, and thus signal, is split between multiple charge 
states. An iterative optimization of sample clean up, LC 
and MS was performed to achieve the limit of detection 
required in plasma.
The use of “superchargers” [22–26] as additives to the 
mobile phase was investigated to increase signal intensi-
ties and ultimately enable quantification of BNP at clini-
cally relevant concentrations. It has been reported that 
the addition of superchargers increases the charge state of 
macromolecules and enhances signal intensities through 
improving ionization efficiency [22–26]. Superchargers 
are additives (often to the LC’s mobile phase) with a high 
boiling point which affects the surface tension of the drop-
lets produced in electrospray. This leads to an increased 
charge density before droplet fission.
Three supercharging reagents were evaluated: DMSO, 
m-nitrobenzyl alcohol (mNBA) and sulfolane. To avoid 
contamination of the LC system and potential changes 
of the chromatographic elution profile, all superchargers 
were post-column infused at 1 μL/min by using a second 
isocratic pump. In Figure 2, the results are reported 
that were obtained by injecting BNP in the absence and 
presence of the three supercharging reagents. It can be 
observed that without any superchargers and in the pres-
ence of DMSO the most intense charge state is 6+ and 
that the signal intensity for the 6+ ion is the highest in 
the presence of DMSO. Dimethyl sulfoxide was therefore 
selected for further experiments and the increase of ion 
signal induced by infusing DMSO at 1 μL/min (0.25%) 
and at 5 μL/min (1.25%) was compared. As no further ion 
signal increase was observed by infusing DMSO at higher 
percentages, DMSO was infused at 1 μL/min (0.25%).
The analytical column was then substituted with 
a 2.6  μm fused core C18  silica particle column. This, 
together with further optimization of the LC and MS con-
ditions enabled the detection of BNP in aqueous solutions 
at 6 fmol/g (20.8 pg/g).
10,000,000
500,000
0
5+ 6+ 7+ 8+
Sulfolane 0.25%
m-NBA 0.25%
DMSO 0.25%
No supercharger
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z
Figure 2: MS ion signal peak areas of the most intense charge 
states (z) detected when analysing 100 pmol/g of BNP in full-scan 
MS mode (m/z 400–800) by infusing superchargers.
The white cylindrical columns represent the integrated areas of the 
different charge states of BNP without any supercharger infused. 
The other columns represent the integrated areas of the different 
charge states of BNP with superchargers.
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A two-step sample clean-up procedure (PPT and SPE) 
was also optimized to enable detection and quantification 
of BNP in plasma.
SPE conditions were initially optimized by using 
aqueous BNP solutions. Although the calculation of the 
recovery of BNP is not a requirement for accurate quan-
tification by IDMS, low recovery compromises method 
sensitivity. An approximate calculation of the recovery 
of BNP during sample clean-up was therefore performed 
to facilitate method development by post-spiking iso-
topically labelled BNP at the same concentration as BNP 
pre-spiked.
The STRATA XL cartridges showed the best retention 
properties for BNP and were selected for further optimiza-
tion. After conditioning, a volume of 100 μL of an aqueous 
BNP solution (1 pmol/g) was loaded and elution was per-
formed with the sequential addition of 2 mL of water con-
taining increasing percentages of acetonitrile (increments 
of 10% from 10 to 100% [v/v]). The washing and elution 
solutions were freeze-dried and reconstituted in water 0.5 
% FA (v/v). BNP was detected in the 20%–40% acetoni-
trile elution steps with a recovery below 50%. The poor 
recovery of BNP was found to be partially caused by oxi-
dation of BNP occurring during SPE. Whereas the use of 
the labeled internal standard compensates for any bias 
during quantification, oxidation of BNP compromises the 
sensitivity of the method and therefore has to be reduced. 
The addition of 45 μg/g of methionine as a scavenger to 
the washing and elution solvents reduced BNP oxidation 
below 1%.
A PPT method was optimized as the first sample 
clean-up step for quantification of BNP in plasma to 
remove most of the high-abundance proteins present and 
enable detection of BNP in plasma. In order to do this, the 
amount of acetonitrile in the precipitation solvent was 
varied to maximize recovery and minimize matrix sup-
pression The optimal PPT solvent was water:acetonitrile 
65:35 (v/v). The recovery calculated with the optimized 
conditions was 58%. The addition of FA during PPT was 
performed to inhibit the activity of the enzymes involved 
in the degradation of BNP in plasma [27, 28].
Stabilization of BNP
In order to verify the stabilization effect of reducing the 
pH of plasma to block protease activity, 10 aliquots con-
taining 60 fmol (209 pg) of BNP were freeze-dried and 
0.5 g plasma was added gravimetrically to each aliquot. 
The precipitation solvent was added at time 0 (T0) to the 
first aliquot and at intervals of 10  min to the remaining 
aliquots. Samples were subjected to SPE, reconstituted 
in water 0.5% FA (v/v) containing an equimolar amount 
of labeled BNP and analyzed by LC-MS/MS. The ratios of 
natural/isotopically labeled BNP are reported in Figure 3 
and show the degradation of BNP over time in the absence 
of the PPT solvent. From this, it is evident that the amount 
of intact BNP decreases rapidly in plasma. The half-life 
of BNP in plasma was found to be 22.6  min and agrees 
with the half-life previously reported [29]. However, when 
the PPT solvent was added to the plasma, BNP did not 
degrade during clean-up and after 2 days stored at 5 °C in 
the LC autosampler, showing the efficacy of the stabiliza-
tion protocol utilized.
Method validation
The limit of detection and quantification, repeatabil-
ity, intermediate precision, linearity and accuracy of the 
method were assessed. Three sets of eight plasma samples 
including a blank containing labelled BNP at 209 pg/g 
and an increasing amount of BNP primary calibrator (15–
150 fmols/g; 52–520 pg/g) were gravimetrically prepared. 
Samples were processed as previously described. The MS 
ion signal area ratio between the natural and labelled BNP 
(AREANAT BNP/AREALAB BNP) was corrected for the gravimetric 
amount of labelled BNP added. The corrected ratios were 
plotted against the gravimetric amount of BNP in each 
sample (mNAT [pg]) to obtain a calibration curve. The cali-
bration points from the three experiments were combined 
to construct the calibration curve displayed in Figure 4 
and the results are reported in Table 1.
Figure 3: BNP degradation profile in the absence of the stabilizing 
PPT solvent.
The SRM MS ion signal ratios of natural (BNP) vs. isotopically 
labeled BNP (BNP*) are plotted against the time BNP spent in 
contact with plasma without the addition of the PPT solvent.
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The accuracy of the method was assessed by calcu-
lating the difference (bias) between the amounts of BNP 
determined from the constructed linear regression curve 
with the gravimetric SI-traceable concentration values. 
This was performed by considering each point of the cali-
bration point as an unknown sample and by quantifying 
its BNP content using the calibration curve obtained with 
the remaining points. The repeatability was calculated as 
the average (n = 3) standard deviation of replicate injec-
tions (n = 3) and the intermediate precision was calcu-
lated as the standard deviation of the individual results 
at each level and reported as relative standard deviations 
in Table 1.
The calculation of the random error associated with 
both the intercept and the slope was performed to deter-
mine the uncertainty associated to the measurements 
performed by linear calibration (x0) [30]. The confidence 
limits were calculated by expanding the standard devia-
tion of the determined concentrations (Sxo) with the t-value 
at 95% confidence level, with (n-2) degrees of freedom. 
Where n is the number of calibration points.
( ) 00 2 xnx t s−±
Analysis of variance (ANOVA) of the calculated con-
centrations at each level from experiments performed on 
different days confirmed that the inter-day variability is 
not statistically significant.
The recovery of BNP from plasma was 58% as previ-
ously reported. However because an isotopically labelled 
internal standard was added before sample clean up, 
recovery was not calculated for each experiment as not 
affecting the quantification results.
A limit of detection of 4.37 fmols/g (15.15 pg/g) was 
measured by calculating the standard deviation of the 
analytical background response of blank samples (n = 9). 
Fifteen femtomoles/gram (52 pg/g) was considered the 
lowest limit of quantification based on visual evaluation 
as the minimum level at which the analyte can be quanti-
fied with acceptable accuracy and precision as shown in 
Table 1.
Analysis of UK NEQAS samples
The method above described was applied to samples from 
the UK NEQAS Cardiac Markers Scheme. Three samples 
were received monthly and processed after receipt. The 
lyophilized plasma samples containing unknown amount 
of BNP were reconstituted by following the instructions 
provided by UK NEQAS. One and half microLitre of the 
PPT solvent was added to each sample upon reconstitu-
tion. Seven plasma samples spiked with the BNP primary 
calibrator in a range of concentrations between 15 fmol/g 
and 155 fmol/g and a blank were also prepared and used 
to construct the calibration curves for each set of samples. 
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Figure 4: Calibration curve obtained from the data points of three 
independent sets of samples.
Each point represents the average of three injections.
Table 1: Concentration levels for the calibration curve and calculated statistics from the validation experiments.
pg/ga Plasma ±U Biasb, pg/g plasma Repeatability Intermediate precision 
0.00 15.49 – – –
53.99 15.41 6.86 4.57 7.92
107.97 15.36 9.82 7.87 9.83
155.85 15.33 7.21 7.07 7.85
206.71 15.31 11.28 14.81 15.71
310.21 15.34 10.51 13.34 12.29
425.01 15.47 20.80 12.78 16.73
527.56 15.62 33.28 16.49 34.60
aGravimetrically prepared concentration of BNP in pg/g; bExpanded uncertainty calculated as described in the Supplementary material 
Section E.
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Thirty femtomole of isotopically labeled BNP were added 
to the calibrants and the UK NEQAS samples. All samples 
were processed and analysed as previously described by 
performing the two-step sample clean-up procedure prior 
to LC-MS/MS analysis. The results from the calibrants 
were plotted as the gravimetric amount of primary cali-
brator vs. the MS area ratios of the natural BNP divided 
by the isotopically labeled BNP. The amount of BNP in the 
UK NEQAS samples was calculated from the mass spectro-
metric ratio natural/isotopically labeled BNP.
The comparison of the LC-MS results with the results 
obtained from three different assays collated through the 
UK NEQAS scheme is shown in Figure 5. The results are in 
agreement with the literature where high cross-reactivity 
of assays with BNP metabolites and circulating proBNP 
lead to overestimation of the amount of BNP present in 
plasma samples. Furthermore, poor characterization of 
calibrants and different specificity of the assays are con-
sidered the major causes of inter-assay discrepancy [31]. 
As the LC-MS method is a targeted method for the 1-32 BNP 
and therefore does not suffer from interferences which 
may be due to the presence of metabolites or proBNP, 
lower results are to be expected. It has to be however high-
lighted that the UK NEQAS samples are stabilized plasma 
samples spiked with BNP. If fragments of BNP are present 
as residues in the depleted plasma before spiking or as a 
result of degradation of BNP post-spiking, their relative 
amount should be constant and discrepancies between the 
assays should be attributed to poor characterization of the 
immunoassay calibrants and different assay specificity. In 
order to confirm this, the same samples were sent more 
than once through the scheme (e.g. S1–S2; S4–S6; S7–S8; 
S10–S12; S11–S15) and the consistent results obtained by 
LC-MS and immunoassays show that the measurement 
bias between assays is not due to a random degradation 
of the spiked samples. The presence of minor percentages 
of degradation products in the samples was confirmed by 
developing an SRM method to monitor for the presence of 
the fragments 3–32, 3–30 and 4–32. The presence of those 
fragments in the UK NEQAS Cardiac Markers Scheme 
samples could be due to minor but consistent degrada-
tion of the spiked BNP into the samples or residues of the 
fragments in the plasma before spiking. As the BNP used 
for spiking plasma samples is a synthetic BNP, peptides 
with portions of the amino acid sequence of BNP could 
be both metabolites and/or impurities of the synthetic 
BNP. The SI-traceable quantified BNP primary calibra-
tor with a known set of impurities was sent to UK NEQAS 
to be used for the preparation of plasma spikes and dis-
tributed through the Cardiac Markers Scheme. Whereas 
a slightly lower uncertainty was observed when the BNP 
primary calibrator was employed, the agreement between 
the different assays did not improve, suggesting that the 
discrepancy between assays is not caused by the presence 
of large amount of impurities in the BNP standard used to 
prepare the UK NEQAS Cardiac Markers Scheme samples. 
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Figure 5: Immunoassay and LC-MS/MS results of the quantification of BNP in samples from the UK NEQAS Cardiac Marker Scheme.
S1 and S2, S3 and S5, and S4 and S6 were the same samples sent blind twice through the scheme. The two dash lines (LC-MSMS HIGH and 
LC-MSMS LOW) represent the highest and lowest limits of the linearity range of the LC-MS method.
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A Passing-Bablok regression [32] was finally carried out to 
visualize the correlation between the LC-MS data and the 
immunoassay data (Figure 6). A correlation was observed 
between the LC-MS data and the data from the three assays 
with larger bias for assay C.
Conclusions
Here we developed a method for SI traceable quantifica-
tion of BNP in plasma at clinically relevant concentrations 
(52–520 pg/g) to be applied to underpin standardization of 
the cardiac marker BNP measurements through provision 
of reference values.
The quantification of the UK NEQAS Cardiac Markers 
Scheme samples by using the candidate reference method 
showed that the reference method results correlate with 
the immunoassay results particularly for the assays A 
and B. The method has the potential to support external 
quality assessment schemes, to improve understanding 
of the bias of immunoassays and to establish reference 
measurement procedures for BNP. Further experiments 
are underway to collect and analyze patient samples with 
the ultimate goal to assess the suitability of the method to 
produce commutable CRM.
The availability of an LC-MS reference method for 
monitoring intact BNP that can be multiplexed to analyse 
BNP metabolites may offer a powerful tool to improve the 
understanding of this promising but disputed biomarker. 
It can be used to generate reliable data to support clinical 
trials of novel therapeutics targeting enzymes involved in 
the BNP metabolism [33, 34]. The development of stand-
ards and reference measurement procedures may finally 
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Figure 6: Results of the Passing-Bablok regression performed to visualise the correlation between the reference method (LC-MS) vs. immu-
noassays (A, B and C).
The dash lines represent the regression from the Passing-Bablock. The plain lines are the theoretical equivalence lines (score 1 and inter-
cept 1). On the x and y axes are reported the values in pg/g of BNP obtained by LC-MS and assay A, B and C.
Brought to you by | University of Reading
Authenticated
Download Date | 6/6/17 11:09 AM
Torma et al.: A reference method for the cardiac marker 1-32 B-type natriuretic peptide      9
facilitate the regulatory approval of LC-MS based in vitro 
diagnostic devices (IVDs) for monitoring intact BNP and 
its metabolites [35].
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